0
Mirum Pharmaceuticals, Inc. Banner Image

Mirum Pharmaceuticals, Inc. has reached its limit for free report views

Work for Mirum Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

Mirum Pharmaceuticals, Inc.

  • Ticker MIRM
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Mirum Pharmaceuticals, Inc. Logo Image
  • 51-200 Employees
  • Based in Foster City, California
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliaryMore atresia. The company has initiated a rolling NDA submission for maralixibat in the treatment of patients with cholestatic pruritus associated with ALGS and expects to complete the submission in the first quarter of 2021. Additionally, the company plans to submit a marketing authorization application to the European Medicines Agency for maralixibat in the treatment of patients with PFIC2 in the fourth quarter 2020.
Mirum Pharmaceuticals, Inc.

Most Recent Annual Report

Mirum Pharmaceuticals, Inc. MOST RECENT 2020 Annual Report and Form 10K

Report Locked. Mirum Pharmaceuticals, Inc. has reached its limit for free report views.

Older/Archived Annual Reports